Orphai Therapeutics
Biotech · Healthcare
Quince completes stock-for-stock takeover of Orphai to refocus on rare lung diseases
May 18, 2026
Quince Therapeutics has acquired Orphai Therapeutics in an all-stock merger tied to a $187M private placement to advance inhaled rapamycin program LAM-001.
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.